Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp,

Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns
- Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 11, 2014

NEW YORK, March 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Align
Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings
(NYSE:LH), Insulet Corporation (NASDAQ:PODD), CareFusion Corporation
(NYSE:CFN), and DexCom, Inc. (NASDAQ:DXCM). Private wealth members receive
these notes ahead of publication. To reserve complementary membership, limited
openings are available at: http://www.AnalystsReview.com/register

Align Technology, Inc. Analyst Notes

On March 6, 2014, Align Technology, Inc. (Align Technology) announced its
participation at the upcoming 26^th Annual Roth Conference, wherein President
and CEO, Thomas M. Prescott, and David White, CFO, will address participants.
The Company informed that the presentation is scheduled on March 11, 2014 from
9:30 a.m. to 10:00 a.m. PT at Dana Point, California. Align Technology added
that a live webcast of the presentation can be accessed via the Company
website, where an archived replay will also be available for approximately
three months. The full analyst notes on Align Technology, Inc. are available
to download free of charge at:


Laboratory Corp. of America Holdings Analyst Notes

On March 4, 2014, Laboratory Corp. of America Holdings (LabCorp) announced
that Chairman and CEO, David P. King, is scheduled to speak at the Barclays
Capital 2014 Global Healthcare Conference in Miami Beach, Florida. The Company
stated that its presentation will take place on Tuesday, March 11, 2014 at
10:45 a.m. ET. LabCorp added that a live audio webcast of the presentation, as
well as its replay, will be available via its website. The full analyst notes
on Laboratory Corp. of America Holdings are available to download free of
charge at:


Insulet Corporation Analyst Notes

On February 27, 2014, Insulet Corporation (Insulet) reported its Q4 2013 and
full-year 2013 results. Insulet posted revenues of $68.5 million, up 18.5% YoY
for the quarter; while annual revenues were up 16.9% to $247.1 million. For
the quarter, the Company's net loss stood at $2.5 million or $0.04 per diluted
share, compared to net loss of $10.2 million or $0.21 per diluted share in Q4
2012. Full-year 2013 net loss was c.$45 million or $0.83 per diluted share,
compared to $51.9 or $1.08 per diluted share in full year 2012.Duane DeSisto,
President and CEO of Insulet, commented, "2013 was one of the most exciting
years in Insulet's history, and I am proud of all that our team accomplished.
We launched the smaller, lighter OmniPod, transitioned all of our OmniPod
customers to the new product in less than six months and established
manufacturing operations capable of producing nearly one million pods per
month. " Insulet stated that for Q1 2014, revenue is expected to be in the
range of $67 million to $71 million; and to be in the range of $295 million to
$315 million for full year 2014.The full analyst notes on Insulet Corporation
are available to download free of charge at:


CareFusion Corporation Analyst Notes

On March 6, 2014, CareFusion Corporation (CareFusion) announced the global
launch of a new line of electrosurgical instruments under the V. Mueller®
brand. According to CareFusion, the new V. Mueller line of bipolar
electrosurgical instruments will consist of both forceps and scissors with
approximately 200 options including non-stick, titanium and irrigating options
to meet the specific requirements of surgeons. The Company added that the new
scissors also feature a single-point connection to the electrical source,
reducing the number of wires attached to the handles to improve
maneuverability and ease-of-use. Commenting on the launch, Andreas Lex, Vice
President and General Manager for V. Mueller and Snowden-Pencer® surgical
instruments for CareFusion, stated, "Expanding our electrosurgical line to
include enhanced bipolar options is good for both our customers and their
patients. V. Mueller has been a trusted name in surgical instruments for
decades, and the new line reinforces our commitment to innovation for today's
modern surgeries." The full analyst notes on CareFusion Corporation are
available to download free of charge at:


DexCom, Inc. Analyst Notes

On March 5, 2014, DexCom, Inc. (DexCom) announced its support for NASCAR
driver Ryan Reed and the American Diabetes Association's Drive to Stop
Diabetes℠ national diabetes awareness initiative.The Company stated that under
the campaign, Dexcom will support Ryan Reed and the Association's Drive to
Stop Diabetes to build awareness about the importance of daily monitoring and
tracking of glucose trends in the management of diabetes. Ryan Reed, NASCAR
driver, commented, "At the age of 17 I received the life-changing news that I
had type 1 diabetes and was told I would never race again. I refused to give
up my racing dream and have since learned to manage my disease through a
balanced diet, exercise and understanding my blood glucose. My Dexcom G4®
Platinum has been my safety belt in tracking my glucose levels on major race
days and in everyday life and for that, I am happy to be working with them."
The Company stated that the Dexcom G4® PLATINUM tracks glucose levels
continuously and uses wireless technology to enable users to view their
glucose levels on demand. The full analyst notes on DexCom, Inc. are available
to download free of charge at:


About Analysts Review

We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.



  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA


SOURCE Analysts Review

Contact: Contact: Adam Redford, +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.